Janelsins MC, et al. - In this nationwide, prospective, observational study conducted within the National Cancer Institute Community Clinical Oncology Research Program, researchers assessed the trajectory and severity of cancer-related cognitive impairment (CRCI) in patients with breast cancer (stage I-IIIC) receiving chemotherapy in specific cognitive domains. In addition, they evaluated CRCI trajectories in other memory aspects as well as in attention and executive function with computerized, paper-based, and telephone-based cognitive tests. Compared with control participants, several other models of computerized, standard, and telephone tests showed significantly worse performance by patients from pre- to post-chemotherapy and from prechemotherapy to 6 months post-chemotherapy. CRCI affects multiple cognitive domains for at least 6 months postchemotherapy in breast cancer patients.